Health ❯Cancer Treatment ❯Precision Engineering of Protein Therapeutics ❯Antibody Drug Conjugate (ADC) Technology
The acquisition aims to boost J&J's oncology portfolio with Ambrx's promising antibody-drug conjugates technology.
